HK1157658A1 - Method for diagnosing cancers expressing the her2 receptor or its truncated variants - Google Patents

Method for diagnosing cancers expressing the her2 receptor or its truncated variants

Info

Publication number
HK1157658A1
HK1157658A1 HK11112126.9A HK11112126A HK1157658A1 HK 1157658 A1 HK1157658 A1 HK 1157658A1 HK 11112126 A HK11112126 A HK 11112126A HK 1157658 A1 HK1157658 A1 HK 1157658A1
Authority
HK
Hong Kong
Prior art keywords
her2 receptor
cancers expressing
truncated variants
diagnosing cancers
diagnosing
Prior art date
Application number
HK11112126.9A
Other languages
English (en)
Inventor
López Joaquín Arribas
Kim Pedersen
Pier-Davide Angellini
Palau Josep Lluis Parra
Sirle Laos
Torres José Baselga
Original Assignee
Fundació Privada Inst De Recerca Hospital Univ
Fundació Privada Institució Catalana De Recerca I
Fundació Privada Inst D Investigació Oncol Gic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Inst De Recerca Hospital Univ, Fundació Privada Institució Catalana De Recerca I, Fundació Privada Inst D Investigació Oncol Gic filed Critical Fundació Privada Inst De Recerca Hospital Univ
Publication of HK1157658A1 publication Critical patent/HK1157658A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
HK11112126.9A 2008-06-02 2011-11-10 Method for diagnosing cancers expressing the her2 receptor or its truncated variants HK1157658A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200801652A ES2342646B1 (es) 2008-06-02 2008-06-02 Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
PCT/EP2009/056976 WO2010000565A1 (en) 2008-06-02 2009-06-05 Method for diagnosing cancers expressing the her2 receptor or its truncated variants

Publications (1)

Publication Number Publication Date
HK1157658A1 true HK1157658A1 (en) 2012-07-06

Family

ID=40911029

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11112126.9A HK1157658A1 (en) 2008-06-02 2011-11-10 Method for diagnosing cancers expressing the her2 receptor or its truncated variants

Country Status (21)

Country Link
US (1) US8389227B2 (xx)
EP (1) EP2293819B1 (xx)
JP (2) JP5753079B2 (xx)
KR (2) KR20160140974A (xx)
CN (1) CN102202692B (xx)
AU (2) AU2009265921B2 (xx)
BR (1) BRPI0914969A2 (xx)
CA (1) CA2727365A1 (xx)
CY (1) CY1115798T1 (xx)
DK (1) DK2293819T3 (xx)
EA (1) EA025218B1 (xx)
ES (2) ES2342646B1 (xx)
HK (1) HK1157658A1 (xx)
HR (1) HRP20141158T1 (xx)
IL (1) IL209769A (xx)
MX (1) MX2010013419A (xx)
PL (1) PL2293819T3 (xx)
PT (1) PT2293819E (xx)
SI (1) SI2293819T1 (xx)
WO (1) WO2010000565A1 (xx)
ZA (1) ZA201009010B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002257132A1 (en) * 2001-04-06 2002-10-21 The Trustees Of The University Of Pennsylvania Erbb interface peptidomimetics and methods of use thereof
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
SG10201408392PA (en) 2009-01-15 2015-01-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
CA2761777A1 (en) * 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
EP2330131B1 (en) * 2009-12-07 2014-10-08 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Antibodies against HER2 truncated variant CTF-611
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
BR112015027607A8 (pt) 2013-05-01 2018-01-23 Five Prime Therapeutics Inc métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes.
EP3116904B1 (en) 2014-03-11 2020-05-06 Molecular Templates, Inc. Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions capable of specifically binding her2/neu/erbb2
ES2723774T3 (es) 2014-03-11 2019-09-02 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
LT3303373T (lt) 2015-05-30 2020-07-10 Molecular Templates, Inc. Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
CA2991259A1 (en) 2015-07-26 2017-02-02 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
WO2017196263A1 (en) * 2016-05-12 2017-11-16 Agency For Science, Technology And Research Anti-erbb-2 antibodies and uses thereof
ES2897217T3 (es) 2016-09-30 2022-02-28 Hoffmann La Roche Anticuerpos biespecíficos frente a p95HER2
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ，インク． 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子
EP3573652A1 (en) 2018-04-17 2019-12-04 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
CN110172448B (zh) * 2019-05-30 2020-07-28 中南大学湘雅二医院 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系
AU2020318781A1 (en) 2019-07-23 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Immune cells defective for SUV39H1
CN110865184B (zh) * 2019-12-04 2023-04-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Srsp蛋白和srsp抗原表位肽的应用及诊断和***的产品
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
JPH10508575A (ja) 1994-08-30 1998-08-25 ユニバーシティ オブ ダンディー アポトーシス誘導剤及び治療法における該誘導剤の適用
DE69725857T2 (de) * 1996-08-14 2004-07-29 The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer Vektor für polynukleotidimpfstoffe
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AU782325B2 (en) 1999-05-14 2005-07-21 Genentech Inc. Treatment with anti-ErbB2 antibodies
NZ517150A (en) * 1999-08-27 2005-01-28 Genentech Inc Dosages for treatment with anti-ErbB2 antibodies
EP1653986A4 (en) * 2003-08-01 2007-03-14 Smithkline Beecham Corp TREATMENT OF CANCERS EXPRESSING P95 SP ERBB2 / SP
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
US8470542B2 (en) * 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95

Also Published As

Publication number Publication date
JP5753079B2 (ja) 2015-07-22
ES2342646B1 (es) 2011-04-26
HRP20141158T1 (hr) 2015-02-13
EP2293819B1 (en) 2014-09-03
IL209769A0 (en) 2011-02-28
ES2342646A1 (es) 2010-07-09
ZA201009010B (en) 2012-03-28
JP2015214546A (ja) 2015-12-03
CN102202692A (zh) 2011-09-28
AU2009265921A1 (en) 2010-01-07
SI2293819T1 (sl) 2015-01-30
EA025218B1 (ru) 2016-12-30
DK2293819T3 (en) 2014-12-08
BRPI0914969A2 (pt) 2015-10-20
CN102202692B (zh) 2014-03-12
MX2010013419A (es) 2011-08-15
JP2011525175A (ja) 2011-09-15
WO2010000565A1 (en) 2010-01-07
CA2727365A1 (en) 2010-01-07
AU2009265921B2 (en) 2015-04-02
EA201001874A1 (ru) 2011-08-30
EP2293819A1 (en) 2011-03-16
ES2528132T3 (es) 2015-02-04
AU2015202854A1 (en) 2015-06-18
US8389227B2 (en) 2013-03-05
KR101785117B1 (ko) 2017-11-07
PT2293819E (pt) 2014-12-09
US20090311262A1 (en) 2009-12-17
PL2293819T3 (pl) 2015-04-30
IL209769A (en) 2016-04-21
KR20110031187A (ko) 2011-03-24
CY1115798T1 (el) 2017-01-25
KR20160140974A (ko) 2016-12-07

Similar Documents

Publication Publication Date Title
HK1157658A1 (en) Method for diagnosing cancers expressing the her2 receptor or its truncated variants
HRP20151108T1 (xx) Antagonisti nogo-receptora
SI2162382T1 (sl) Polnilni sistem
AP2011005719A0 (en) Anti-IGF antibodies.
HK1156638A1 (en) Human anti-alpha-synuclein autoantibodies
GB201020970D0 (en) Early entry
IL212551A0 (en) Cxcr4 receptor compounds
GB0821100D0 (en) Antibodies
EP2300828A4 (en) SCREENING SYSTEM FOR ANTIGENS
HRP20141257T1 (xx) Protutijela za her2-krnju varijantu ctf-611
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
GB0810457D0 (en) Gold system
GB0921999D0 (en) Early entry
ZA201100868B (en) Tungsten-based vacancy-keggin-type heteropolyanion for hydrocracking
EP2029771A4 (en) DIAGNOSTIC METHOD OF MYOPATHY
EP2312337A4 (en) TECHNIQUE FOR DETECTING CRANIAL NERVE DISEASE
ZA201006099B (en) Anti-tyrp1 antibodies
SI2307304T1 (sl) Polnilni sistem
ZA201007976B (en) Anti-pirb antibodies
GB0922083D0 (en) Early entry
GB0922210D0 (en) Car parkng apparatus
GB0920030D0 (en) Early entry
GB0818356D0 (en) Antibodies
PL384536A1 (pl) Jarzmo dolne do górniczych strzemion
ZA201103566B (en) Biomarker for diagnosing cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190604